Table 3 Treatment-associated changes in clinical variables by genotype groups

From: The role of FKBP5 genotype in moderating long-term effectiveness of exposure-based psychotherapy for posttraumatic stress disorder

  t 1 (pretreatment) t 2 (4 months) t 3 (10 months) Change score a Effect size Cohen’s D b
N PTSD diagnosis (%)
 C/C 13 (100) 4 (31) 0 (0)c   
 T allele carrier 30 (100) 7d (29) 13 (43)   
Mean PDS score (s.d.)
 C/C 17.69 (4.44) 8.15 (5.00) 3.92 (2.78) −13.58 (6.37) 3.72
 T allele carrier 16.63 (4.94) 7.90 (6.03) 9.37 (6.73) −7.27 (5.60) 1.23
Mean M.I.N.I. suicidality score (s.d.)
 C/C 12.69 (8.31) 5.31 (6.47) 2.08 (4.94) −11.08 (8.67) 1.55
 T allele carrier 11.90 (11.21) 8.45 (10.60) 7.37 (8.31) −4.53 (6.85) 0.45
Mean PDS intrusions score (s.d.)
 C/C 4.85 (2.51) 2.54 (1.51) 1.50 (1.68) −3.08 (3.32) 1.57
 T allele carrier 4.53 (2.30) 1.83 (2.25) 2.53 (2.36) −2.00 (3.25) 0.86
Mean PDS avoidance score (s.d.)
 C/C 6.38 (2.10) 2.46 (1.94) 0.83 (1.27) −5.50 (2.54) 3.20
 T allele carrier 6.07 (2.03) 2.52 (2.23) 3.17 (2.36) −2.90 (2.29) 1.32
Mean PDS hyperarousal score (s.d.)
 C/C 6.46 (2.15) 3.15 (2.41) 1.58 (1.00) −5.00 (2.45) 2.92
 T allele carrier 6.03 (2.76) 3.55 (2.68) 3.67 (2.68) −2.37 (2.51) 0.87
  1. Abbreviations: M.I.N.I., Mini International Neuropsychiatric Interview; PDS, Posttraumatic Diagnostic Scale; PTSD, Posttraumatic Stress Disorder.
  2. aChange score describes the difference between pretreatment and 10-month follow-up assessment.
  3. bCohen’s D describes the within-group treatment effect size between pretreatment and 10-month follow-up assessment.
  4. cOne individual was not found for 10-month follow-up.
  5. dOne individual was not found for 4-month follow-up.